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Abstract Coronary heart disease (CHD) often presents
suddenly with little warning. Traditional risk factors are
inadequatetoidentifythe asymptomatichigh-riskindividuals.
Early identification of patients with subclinical coronary
artery disease using noninvasive imaging modalities would
allow the early adoption of aggressive preventative interven-
tions.Currently,itisimpracticaltoscreentheentirepopulation
with noninvasivecoronaryimaging tools. Theuse ofrelatively
simpleandinexpensivegeneticmarkersofincreasedCHDrisk
can identify a population subgroup in which benefit of
atherosclerotic imaging modalities would be increased despite
nominal cost and radiation exposure. Additionally, genetic
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Introduction
The genetic revolution for some individuals has yet to
begin whereas for others it came and was a disappointment.
Although such a statement may be a cliché, it does not
reflect the recent genetic efforts of the scientific community.
The quest to elucidate the genetic factors predisposing to
common diseases is based on well-founded progress. The
revolution did not gain momentum until 2005, and in
6 years the progress has been nothing short of remarkable.
The high-throughput microarray platforms employed to
perform genome-wide association studies (GW AS) have
already provided more data than can be currently appraised
or applied [1]. Nearly 1000 loci have been shown to
associate with common diseases [2]. The critics are quick to
indicate the effect of any one locus is small and unlikely to
revolutionize therapy or usher in the era of personalized
medicine. Cholesterol has been known to be a risk factor
for coronary artery disease (CAD) since the 1950s. The first
specific drugs to lower cholesterol were produced in 1987,
yet we are still working to overcome barriers that prevent
such testing and therapy for primary and secondary
prevention. This is just the beginning of the genetic
revolution and its success is likely to inspire and accelerate
future efforts. First, in regard to heart disease, GW AS have
revealed that there are many mechanisms inducing CAD
and myocardial infarction (MI) independent of known
traditional risk factors [3]. Second, there are many more
genetic factors yet to be identified for heart disease and
other common diseases. Third, we can expect new drugs to
be developed as a result of targeting these new mechanisms.
Fourth, now is the time to acquire the education and
infrastructuretoproperlyapplygenetictestingandprevention.
It has been stated that heart disease can be eliminated in
this century [4]. This exuberant statement was stimulated
by the observation that most types of heart disease are
preventable. Clinical trials have shown that modulating
current risk factors prevents 30% to 40% of heart disease
[5]. Epidemiology and family studies have long docu-
mented that approximately 50% of susceptibility for heart
disease is genetic [6]. We should hope and prepare for the
day when these genetic factors are elucidated. Comprehen-
sive prevention and treatment will be possible only if we
know the genetic predisposition [7]. There are currently
over 30 loci proven to be associated with increased risk for
CAD [8]. While caution is advised, there are costs to
delaying the implementation of genetic testing and it may
be productive to consider provisional approaches [9]. There
are some benefits to be derived currently from testing for
genetic predisposition. This review is a description of
examples illustrating this benefit.
Atherosclerosis is often a slow-moving and silent disease
until the eventual development of a sudden coronary event
or the appearance of symptoms of myocardial ischemia.
Sixty-seven percent of out-of-hospital emergency medical
services–treated cardiac arrests have no symptoms within 1
hour of death [10]. However, many individuals develop
coronary atherosclerosis and lead active lives, eventually
succumbing to a fatal disorder not necessarily related to
coronary atherosclerosis. The relatively recent concept of
plaque instability as the acute etiology of a clinical event is
now embraced by the medical community and highlights
the important difference between the presence of coronary
atherosclerosis and a clinical event [11]. Nevertheless, the
more atherosclerosis that is present in the coronary tree, the
greater the likelihood that a clinical event will occur [12].
Thus, detection of evidence of coronary atherosclerosis
prior to an event allows aggressive and individualized
preventive measures to be taken that have the potential to
significantly reduce the probability of future coronary
events in a primary prevention population.
The approach embraced by the general medical commu-
nity for primary prevention may be termed “treat by the
numbers”. As exemplified by the Adult Treatment Panel
(A TP) III guidelines, blood lipid levels above a specific
number are to be considered as reflecting increased risk and
thus deserving of treatment [13]. Consequently, a number
below the predefined level implies no increased risk and
thus does not require treatment. This approach has
encouraged physicians to simply assume elevated or normal
risk based on statistical relations for an “average” individual
and ignores the great heterogeneity in the human population.
Indeed, it is established that most patients with coronary
events would not fit into the average guidelines and thus
would not have received aggressive risk management [13].
According to the A TP III guidelines, low-density lipoprotein
cholesterol (LDL-C) reduction is the primary focus for risk
reduction [14]. However, in a large study with 244,000
person-years of follow-up, it was reported that statin use in
the primary prevention population did not significantly
reduce all-cause mortality, nor was there any material
relationship between mean LDL-C reduction and reduction
in all-cause mortality [15￿]. Although many statin-induced
LDL-C reduction studies have demonstrated an approxi-
mately 27% relative risk reduction, this actually equates to
only a 3.4% absolute risk reduction and leaves many
prevention patients at increased risk despite statin therapy
[16].
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event is the known presence of atherosclerosis. If a primary
prevention patient is found to have atherosclerosis, they
should be moved into the secondary prevention algorithm
allowing for more aggressive preventive treatment strategies.
One approach to this is to utilize noninvasive imaging to
detect asymptomatic coronary atherosclerosis early. However,
this approach has been criticized as exposing too many
primary prevention patients to either increased personal
expense or unnecessary radiation exposure to CT scanning,
although both the amount of radiation and the cost have been
decreasing with the use of state of the art equipment [17]. A
potentially more efficient approach that could improve the
risk/benefit ratio of noninvasive imaging would be to
categorize the primary prevention population into higher
and lower risk utilizing tools that improve upon standard risk
factor assessment. One of these tools is the utilization of
genetic risk markers either through phenotypic tests or
genotypic tests. One of the most powerful tests is simply a
family history of premature CHD; however, recent advances
in the field of genetics allow more accurate assessment of
CHD risk. Once the presence of atherosclerosis is identified
through noninvasive imaging, genetic tests can also be
utilized to help the clinician determine the most effective
treatment for the individual patient [18].
Even though the promise of clinically useful genetic tests
has been around for decades, a few relatively recent
scientific breakthroughs have allowed the promise to
become a reality. Although DNAwas isolated by Miescher
in 1869, and Watson and Crick received the Nobel Prize for
elucidating the double helix in 1954, it was Kary Mullis’
invention of the polymerase chain reaction in 1985, for
which he shared the Nobel Prize in 1993, that catalyzed the
field of human genetic research. In 2001, a draft sequence
of the human genome was presented by both V enter and
Collins that provided the road map for future research plans
and discoveries [19, 20]. Most recently, the invention of
“gene chip” technology has allowed 1 million single
nucleotide polymorphisms (SNPs) to be assessed in each
individual in an investigation and has spawned the GW AS
approach [21]. Advances in the technology of genetic
analysis have significantly reduced the cost to consumers
and provide the opportunity of practical tests with clinical
utility.
It has been stated that in order for predictive risk scores
to be useful, “A distinction must be made between
population and individual targeting for the evaluation and
management of the CVD risk factor profile. … In order to
succeed, primary prevention strategies for individual
patients should be simple and personal” [22]. Two clinically
available tools to enhance “personalization” include genetic
tests and noninvasive imaging for individual patient
management.
Clinical utility of inherited cardiovascular risk testing
currently exists utilizing both phenotypic and genotypic
markers. These markers can improve the accuracy of CHD
risk prediction, help in the selection of a treatment most likely
tobesuccessful,andbeinformative infamilycounseling[23].
One major impediment to widespread clinical adoption of
this concept involves privacy issues. Privacy issues were
addressed in the Federal genetic nondiscrimination bill
(Genetic Information Nondiscrimination Act H.R. 493 of
2008), which was passed by both the House of Representa-
tives and the US Senate on May 22, 2008, and signed into
law by President George W. Bush.
This article addresses the utility of genetic tests to identify
high-risk subgroups, discusses a sample of practical genetic
tests that may guide risk prediction and treatment decisions,
and raises the issue of combining genetic tests with
noninvasive imaging to enhance identification of individuals
at high risk for CHD.
Detection of High-Risk Subgroups through Genetic
Testing: 9p21
In 2007, the first common gene for coronary artery disease
(9p21) was identified almost simultaneously by two
separate groups using a GW AS [24, 25]. This polymor-
phism is located on the short arm (p) of chromosome 9 in
the band region 2.1 and so it is referred to as 9p21. In the
Ottawa Heart Study, the initial mapping of 9p21 was in an
Ottawa population and it was subsequently confirmed in
independent populations from Dallas, Houston, and Denmark
for a total of23,000Caucasiansubjects.The9p21 risk variant
is very common, occurring in 75% of the Caucasian
population, with 50% inheriting a single copy (heterozygous)
and 25% two copies (homozygous). Individuals have an
increased relative risk for CHD of about 40% and 20% for
those with two or one copy of the 9p21 variant, respectively.
Perhaps the most exciting, unexpected bonus is that 9p21
risk is independent of all known risk factors, namely,
cholesterol, hypertension, diabetes or obesity. This clearly
implies a novel, previously unknown pathway contributing
to the genesis of atherosclerosis. Simultaneously, Helgadottir
et al. [25]s h o w e d9p21 was associated with a similar
increased risk for MI.
Over the next 6 months, multiple studies throughout
Europe involving over 65,000 individuals confirmed 9p21
to be a common risk factor for CHD in Caucasians [26–28].
Studies have also confirmed that 9p21 has a similar
frequency and increased risk for CHD Chinese [29],
Korean/Japanese [30], and East Indian [31] populations.
The 9p21 variant does not appear to be associated with
increased risk for CHD in individuals of African descent
[31]. The 9p21 locus has also been confirmed to be a risk
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[32] and ischemic stroke [33]. Unfortunately, the 9p21 region
does not contain a protein coding gene but rather a long non-
coding RNA (ANRIL) that presumably regulates other genes
in a novel pathway predisposing to CHD. A recent study
suggests ANRIL may mediate its risk for atherosclerosis
through the interferon pathway [34]. Since the initial 9p21
study, over 30 genes have been identified and replicated in
independent populations of large sample size to be associated
with increased risk for CHD [8]. These risk loci were
mapped in a discovery population of over 80,000 cases and
controls and replicated in an independent population of over
50,000. Most of these genes occur in the population with a
frequency varying from 13% to 90% and are associated with
a 6% to 20% increased risk of CHD per allele. Notably, the
risk associated with most of these alleles is independent of
traditional CHD risk factors. These studies were performed
using the interchangeable phenotype of MI or coronary
atherosclerosis and genotyped via GW AS using a microarray
with over 2 million SNPs [35]. Recently, a locus was
identified that is associated with increased risk for MI
without any risk for atherosclerosis [36]. More specific
phenotypes or sub-phenotypes for atherosclerosis are
expected to emerge from these studies.
Mostrecently, the presenceofthe 9p21 risk allele has been
shown to improve standard risk prediction models. The
Atherosclerosis Risk In Communities (ARIC) risk equation
c a nb eu s e dt oa s s e s sa ni n d i v i d u a l ’s risk potential and
includes a family history of heart disease. In 2009, Brautbar
et al. [37￿] showed that the addition of 9p21 information to
the ARIC risk score reclassified 32.9% of individuals into
more accurate risk categories when in the two moderate-risk
groups (5%–10% and 10%–20%), and the reclassification
index was improved in 45.1% in all risk groups (Table 1).
In 2010, Dandona et al. [38] reported that there was a
strong direct association between the proportion of early
onset three-vessel disease and the gene dose of 9p21
(rs1333049). The authors concluded that given its (9p21)
ability to predict risk within a CHD population, genotyping
9p21 may be useful not only in determining risk for
development of disease but also for risk stratification
among patients with documented CAD. This documented
relationship between 9p21 homozygosity and arteriographic
severity suggests that noninvasive imaging of the coronary
arteries may be most productive in 9p21 homozygous
subjects, who comprise approximately 25% of the general
population.
T h ep r e s e n c eo ft h e9p21 polymorphism does not
guarantee the presence of CHD but represents an indepen-
dent risk predictor that helps identify a group at higher risk
than previously thought based on traditional risk factor
assessment. This creates the opportunity to use genetic tests
to identify individuals who are more likely to benefit from
noninvasive imaging and helps improve the risk/benefit of
CT scanning. Three factors contribute to this rationale
approach to primary prevention screening. First, 9p21
identifies risk for CHD independent of traditional risk
factors. Second, it has been reported that 9p21 homozygous
individuals have more severe coronary atherosclerosis
anatomic CHD than others. Third, there remains some
controversy regarding potential adverse effects of radiation
exposure associated with widespread public screening with
fast CT. Use of this once-in-a-lifetime genetic test helps to
identify 25% of the primary prevention population that may
benefit most from fast CTscreening.
This approach to more accurate risk prediction has taken
another step forward by utilizing a panel of SNP tests that
capture a wider range of genetic variation [39]. Davies et al.
[40] have reported that a collection of 12 SNPs, including
9p21, improves CHD prediction over and above traditional
risk factors (Fig. 1). The incorporation of over 30 SNPs
shown to increase risk for CHD should make for even
greater predictability and risk stratification for patients
being considered for cardiac imaging such as fast CT
coronary angiography.
Detection of High Risk Subgroups through Genetic
Testing: LPA
Unlike 9p21, some genetic tests can identify a high-risk
group but have a low population frequency. However, such
tests may have clinical utility in the majority of the
population that does not carry the polymorphism.
ARIC 10-year risk ARIC 10-year risk Reclassified, n (%)
0%–5% 5%–10% 10%–20% >20%
0%–5% 97.8% 2.2% 0 0 87 (2.2%)
5%–10% 7.9% 82.9% 9.2% 0 319 (17.1%)
10%–20% 0% 7.0% 84.2% 8.8% 382 (15.8%)
>20% 0% 0% 10% 90% 185 (10.0%)
Total, n 3936 1805 2394 1869
Table 1 Reclassification of risk
when predictive values of 9p21
genotyping are added to the
ARIC risk score in 998 subjects
followed for a mean of
14.6 years
ARIC—Atherosclerosis Risk in
Communities study
(Data from Brautbar et al. [37￿].)
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primary care physicians is the potential risk/benefit of daily
aspirin use to reduce cardiovascular disease risk. Previous
investigations have indicated that in the secondary prevention
population, the benefit of daily aspirin and heart disease risk
reduction outweighs the potential harm associated with daily
aspirin use. However, in the primary prevention population
theanswerislessclear.TheUSPreventiveServicesTaskforce
providedsomeguidancein2009byrecommendingcut-points
based on the Framingham Risk Score (FRS) to identify
patients who are more or less likely to derive heart disease or
stroke prevention benefit from daily aspirin treatment [41].
The risk/benefit cut-point was defined by age and gender and
was established at the FRS level at which the number of
CHD events or strokes prevented equaled the number of
gastrointestinal bleeds caused.
The LP A gene encodes the apolipoprotein(a) component
of Lp(a), and a polymorphism in the protease-like region of
the protein. It has been shown to provide useful information
to help balance the risk/benefit ratio of daily aspirin use
intended to reduce CHD risk. In the Women’s Health study,
25,815 middle-aged women were randomized to aspirin or
placebo. After 10 years of follow-up, women with the LP A
risk variant in the placebo group experienced significantly
more cardiovascular (CV) events (P<0.0005), but if women
with the LP A risk variant were randomized to aspirin, their
CV event rate was equal to the non-carriers in both the
placebo and aspirin group [42￿]. Aspirin therapy had no
effect on reducing CVevents in the women without the LP A
risk variant. This risk variant is found in approximately 4%
of the population of European ancestry. However, the clinical
utility may be in giving daily aspirin therapy advice to the
96% of people who are not carriers of the LP A risk variant,
thus potentially reducing the risk of gastrointestinal compli-
cations of long-term aspirin use. The number needed to treat
to prevent one CVevent in the Women’s Health Study with
aspirin was 625 in LP A non-carriers but only 37 in the
women who carried the LP A risk variant.
Detection of High Risk Subgroups through Genetic
Testing: APO E
One of the most common genes affecting LDL-C levels
codes for apoprotein E, which has three major isoforms
designated as E2, E3, and E4 [43]. Apo E with the common
amino acid sequence is termed E3. Less common amino
acid variants can result in E proteins termed E2 or E4. The
most common variant, E3, has a frequency of approximately
0.78, while E4 has a frequency of 0.15, and E2 a frequency of
0.07. Apo E4 is a common contributor to elevated LDL-C
and is found in approximately 25% of the population. The
relatively rare Apo E2/2 genotype is the underlying cause for
Type III hyperlipidemia. Comparison of individuals with the
E3/2 versus E3/4 genotype revealed a difference in LDL-C
levels of around 20 mg/dL or about 14% [44].
Apo E genotyping can be beneficial in CHD risk
prediction. A meta-analysis of Apo E genotype and CHD
risk indicates a lower CHD risk for carriers of the E2 allele
and slightly higher risk for carriers of the E4 allele [44].
Eighty-two studies were analyzed. The positive relationship
between the E4 allele and blood LDL-C levels was
confirmed and found to be significant and approximately
linear. For the Apo E genotype, compared with E3/3, the
odds ratio for CHD was 0.80 (95% CI, 0.70–0.90) for E2/E2
individuals,and1.06(95%CI,0.99–1.13)forE4carriers ina
study of 21,331 cases and 47,467 controls. In a GW AS,
genetic variation in the Apo E gene locus was found to be
significantly associated with variation in blood cholesterol
measurements [45]. This common contributor to elevated
LDL-C is one major factor responsible for the familial
predisposition to CHD [46].
LDL-C reduction in response to statin therapy is quite
variable and some, but not all studies, have reported a
genotype-specific association and LDL-C response to statin
treatment [47]. Subjects with the Apo E4 genotype tend to
have higher baseline LDL-C and less reduction in LDL-C
in response to statin treatment. PROVE IT-TIMI 22 was a
prospective study in acute coronary syndrome patients
randomized to 40 mg/d of pravastatin versus 80 mg/d of
atorvastatin. In this investigation, subjects with the Apo E2
allele had the greatest LDL-C reduction and those with the
Apo E4 allele the least LDL-C reduction in response to
either statin [48]. The Apo E genotype classification
influenced the proportion of subjects who achieved a
clinically meaningful LDL-C target, with more than 25%
of E4 carriers failing to meet recommended LDL-C goals.
Fig. 1 A collection of 12 single nucleotide polymorphisms (SNPs),
including 9p21, improves coronary heart disease prediction over and
above traditional risk factors. (From Davies et al. [40].)
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Once CHD is diagnosed in a patient, either through
noninvasive imaging or clinical criteria, the next medical
issue is the selection of treatments that have the best chance
for benefit while avoiding potential side effects in patients
that may have less cardiovascular benefit. One such
example is the KIF6 polymorphism, which identifies a
patient subgroup that benefits the most from statin
treatment in regard to clinical event reduction.
This common variant occurs in the kinesin-like protein 6
gene (KIF6), in which arginine replaces tryptophan
(Trp719Arg) and is present in approximately 60% of the
Caucasian population in sub-studies of major prospective
trials [49￿]. Relevant to treatment decisions, the statin-
induced clinical event reduction benefit has been found to
be greater in carriers of the KIF6 risk variant compared to
those who are not carriers in four major randomized clinical
trials. Carriers of the KIF6 polymorphism have substantially
fewer CHD events during pravastatin and atorvastatin
therapy, whereas non-carriers do not despite similar on-
treatment levels of LDL-C and C-reactive protein (CRP). In
addition, the reduction of CHD events from intensive
therapy (eg, high-dose atorvastatin) in the KIF6 polymor-
phism individuals is observed as early as 30 days after
initiation of therapy. Consequently, assessment of KIF6
carrier status holds promise for stratification of coronary
event risk and for selection of optimal therapy in primary
and secondary CHD prevention. In randomized trials of
pravastatin or atorvastatin therapy, the number needed to
treat to prevent a single CHD event ranged from 10–20 for
KIF6 carriers compared with 72 to 100 for non-carriers in
the CARE, WOSCOPS, PROVE IT-TIMI 22, and PROS-
PER studies (Table 2). The clinical event differential
response to statin therapy has not been reported in all
studies. In the prematurely terminated JUPITER trial of
rosuvastatin, low-risk KIF6 carrier individuals (hazard ratio
[HR] 0.61; 95% CI, 0.43–0.87) received the same clinical
event reduction as the KIF6 non-carriers (HR 0.59; 95% CI,
0.39–0.88) [50]. In a retrospective analysis of the Heart
Protection Study, KIF6 carriers and non-carriers received
similar clinical event reduction benefit from simvastatin
treatment [51]. The KIF6 polymorphism may provide
clinicians with a new tool with which to further personalize
risk stratification and prediction of clinical event reduction
benefit from statin therapy.
One medication that has been successfully utilized in
National Institutes of Health–funded heart disease regression
trialsisnicotinicacid[52]. Although the physiologic benefit is
documented and includes reduction in triglycerides, reduction
in atherogenic small LDL, reduction in Lp(a), and increased
high-density lipoprotein cholesterol (HDL-C) and HDL2,
nicotinic acid remains underutilized in part due to annoying
but tolerable side effects [53]. One polymorphism in the
promoter region for hepatic lipase (HL) has been shown to
identify a subgroup of CHD patients that respond better than
others to nicotinic acid in regard to HDL-C and HDL2
elevation linked to improved arteriographic outcomes. In FA TS,
51% of the population was homozygous for the HL514T
polymorphism and they exhibited lower HDLC and HDL2 at
baseline but much greater HDL-C and HDL2 increase
following treatment [54]. Coronary stenosis change in this
group was -2.1% compared to -1.1% in the heterozygous
group and +4.0% in the non-carrier group [54]. Use of
relatively simple SNP testing can identify subgroups of
patients that benefit more, or less, from specific drug therapy.
Genetic testing and noninvasive imaging of preclinical
atherosclerosis provides the clinician with two powerful tools
with which to tailor their approach to the individual patient.
Genetic Tests, Imaging, and Family Members
AlthoughitisacceptedthatafamilyhistoryofCHDisamajor
risk factor for an individual patient, there is little guidance in
the general medical community for the evaluation of family
members of patients with “premature” CHD.
A family history of premature heart disease is one of the
most powerful determinants of CHD risk and is independent of
the common CHD risk factors such as smoking, hypertension,
diabetes, and some lipids [55]. Retrospective studies have
indicated that the risk of CHD in siblings of victims of
premature CHD is approximately 50% for men and less for
women [56]. In siblings of premature CHD patients, the risk
of dying from CHD was 5.2 times higher than in a population
without such a family history. The CHD risk associated with a
family history of premature CHD is higher than the two- to
threefold CHD risk associated with cigarette smoking [57].
Numerous prospective studies of the risk for CHD in first-
degree relatives havebeen conducted [58]. The age definition
of “premature” is relative and perhaps misleading. In the
Nurses Health Study, the risk for non-fatal MI was 5.0 if a
family history of fatal CHD prior to age 60 years was
Table 2 Number of patients needed to treat with a statin drug in four
statin clinical trials to prevent one event over 2 years in patients
determined to be KIF6 risk allele non-carriers and KIF6 risk allele
carriers
Study All
patients, n
KIF6
non-carriers, n
KIF6
carriers, n
CARE 34 72 20
WOSCOPS 46 >100 18
PROSPER 24 83 16
PROVE IT 16 125 10
(Data from Li et al. [49￿].)
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60 years of age was present. Thus, although the presence of
CHD at an age <60 years indicated a very high risk, a history
in a family member >60 years of age was still substantial and
clinically informative. These prospective investigations
indicate that the risk of MI is at least twofold greater if a
family history of CHD is present and that the CHD risk is
independent of classic CHD risk factors.
The use of noninvasive imaging has contributed to our
understanding of the importance of family history in predict-
ing CHD risk. The finding that the risk for a CHD event is
approximately50%insiblingsofprematureCHDpatientshas
been reproduced utilizing noninvasive imaging [59]. In 1619
asymptomatic male subjects who underwent coronary artery
calcium (CAC) testing, a family history of CHD in a first- or
second-degree relative was reported to be highly predictive
of a positive CAC score with odds ratios approaching 1.50
[60]. In a similar study of 8549 asymptomatic individuals, a
family history of CHD in a parent increased the odds ratio to
1.3 in men and women, and a family history of CHD in a
sibling increased the odds ratio to 2.3 [61]. The association
of a family history of a positive CAC score is particularly
powerful in siblings. Seventy-eight percent of individuals
reporting a sibling with known CHD had a positive CAC
score. With the emergence of noninvasive imaging modali-
ties that do not expose the individual to ionizing radiation
that can be performed in a mobile manner at a relatively
nominal cost, the ability to screen large numbers of people
will be possible. The emerging role of carotid and peripheral
ultrasound techniques as well as the evaluation of endothelial
function are two such modalities. Carotid intimal medial
thickness measurements have been shown to not only
identify individuals at higher risk for events, but there are
emerging data that this modality can be utilized to follow
preventive treatment strategies [62]. The measurement of
endothelial dysfunction may allow the identification of
younger groups of individuals at risk for events prior to
visual identification of plaque using CT or ultrasound
techniques [63]. Abnormal endothelial function is an early
marker of subclinical atherosclerosis and increased cardio-
vascular risk. However, assessment has been limited to
research laboratories under highly controlled conditions.
Recently, peripheral amplitude tonometry has been validated
as a novel technique for endothelial function assessment and
suitable for use in ambulatory clinical practice [64].
The identification of individuals with the at-risk geno-
type is a one time test that can be performed early in the
individuals life, with the potential for the noninvasive
imaging modality to be utilized throughout the remainder of
his/her life to follow and allow adjustments to the
preventative treatment strategy. In this regard, noninvasive
imaging screening in families with known CHD may be
beneficial, particularly in family members with a pheno-
typic or genotypic expression of CHD risk similar to the
family member with known CHD.
Conclusions
Both genetic tests (phenotype and genotype) and noninvasive
imaging modalities have been shown to identify groups of
individuals at substantially increased risk for coronary events.
Furthermore, genotype tests have demonstrated clinical utility
in guiding therapies by identifying subgroups that have the
best chance of achieving the desired outcome. Future utility
mayincludeprofessionalgroupsthatareathighCHDriskand
presumablylinkedtotheirprofessionalactivities.Professional
firefighters are known to be at a two- to threefold increased
risk of CHD and recently it was reported that approximately
one third have subclinical CHD not linked to traditional risk
factors [65￿]. Because family history is such a powerful
predictor of CHD events, the combination of simple and
relatively inexpensive genetic tests to clarify risk, followed
by noninvasive imaging in the high-risk population, allows
identification of a group most deserving of aggressive and
individualized treatment.
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